Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Cognitive function · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Word retrieval · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Overall language abilities · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Cognitive function · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Quality of life · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (Lichtiger index) (4 weeks) · Patients with active mild to moderate ulcerative colitis
1 finding from 1 review
Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics showed no clear difference in clinical relapse (6 months) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (partial Mayo score) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review